Jill Beraud - May 3, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
Director
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
May 3, 2023
Transactions value $
$0
Form type
4
Date filed
5/5/2023, 05:13 PM
Previous filing
Apr 21, 2023
Next filing
May 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $0 +3.53K +14.1% $0.00 28.6K May 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVNC Stock Option (Right to buy) Award $0 +5.92K $0.00 5.92K May 3, 2023 Common Stock 5.92K $33.61 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents an annual restricted stock award (the "RSA") granted pursuant to the Company's Amended and Restated Non-Employee Director Compensation Policy (the "Compensation Policy"). The shares underlying the RSA shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Ms. Beraud's Continuous Service (as defined in the Company's 2014 Equity Incentive Plan (the "Plan")) through such vesting date.
F2 The shares subject to the stock option shall vest on the earlier of (a) the one year anniversary, May 3, 2024 and (b) the day immediately prior to the date of the Company's next annual stockholder meeting, subject to Ms. Beraud's Continuous Service through such vesting date. The stock option represents an annual grant pursuant to the Compensation Policy.